ArticleHuman vaccines & immunotherapeutics2023
Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.Human vaccines & immunotherapeutics · 2025Pooled it
- Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Online Decision Support for Implementing Evidence-Based HPV Vaccination Strategies in Texas Safety-Net Pediatric Clinics: Impact on HPV, MCV, and Tdap Initiation.Healthcare (Basel, Switzerland) · 2026Article
- Electronic Health Record Alerts for Early Human Papillomavirus Vaccination.JAMA network open · 2026Article
- Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10.Human vaccines & immunotherapeutics · 2025Article
- Potential acceptance of HPV vaccination at ages 9-10 in the United States among parents of HPV vaccine-naïve children.Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination coverage, hesitancy, and barriers: Insights from a serial cross-sectional study in Shanghai, China (2019-2024).Human vaccines & immunotherapeutics · 2025Article
- HPV vaccination in community health organizations: what is going right and how can it be replicated?Cancer causes & control : CCC · 2025Observational
- Health Equity and Human Papillomavirus Vaccine Interventions for Adolescents: A Systematic Review.Vaccines · 2025Review
- Review
- Article
- Article
- Update on Oral and Oropharyngeal Cancers: A guide for oral health care providers.Journal of dental hygiene : JDH · 2024Article
- Assessing the long-term implications of age 9 initiation of HPV vaccination on series completion by age 13-15 in the US: projections from an age-structured vaccination model.Frontiers in pediatrics · 2024Article
- Human papillomavirus vaccination at the first opportunity: An overview.Human vaccines & immunotherapeutics · 2023Review
- Age nine is possible: Improving age 9 HPV initiation through a national quality improvement initiative during the COVID-19 pandemic.Human vaccines & immunotherapeutics · 2023Article
- Mothers' perceptions and attitudes about HPV vaccination initiation among 9- and 10-year-olds.Human vaccines & immunotherapeutics · 2023Article
- Evidence supporting the initiation of HPV vaccination starting at age 9: Collection overview.Human vaccines & immunotherapeutics · 2023Article
- How to make effective HPV vaccine recommendations starting at age 9.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vaccination for Human Papillomavirus (HPV) is important to reduce rates of cervical and oropharyngeal cancer. We aimed to evaluate if a program to initiate HPV vaccination at 9 years improved initiation and completion rates by 13 years of age. Data on empaneled patients aged 9-13 years from January 1, 2021 to August 30, 2022 were abstracted from the electronic health record. Primary outcome measures included HPV vaccination initiation and series completion by 13 years of age. The secondary outcome measure was missed opportunities for HPV vaccination. In total, 25,888 patients were included (12,433 pre-intervention, and 13,455 post-intervention). The percentage of patients aged 9-13 with an in-person visit who received at least 1 dose of HPV vaccine increased from 30% pre-intervention to 43% post-intervention. The percentage of patients who received 2 doses of vaccine increased from 19.3% pre-intervention to 42.7% post-intervention. For the overall population seen in-person, initiation of HPV vaccination by age 13 years increased from 42% to 54%. HPV completion increased as well (13% to 18%). HPV vaccination initiation at 9 years of age may be an acceptable and effective approach to improving vaccination rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.